When do the patents on VITAMIN A expire, and when will generic VITAMIN A be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Banner Pharmacaps	VITAMIN A	vitamin a palmitate	CAPSULE;ORAL	080702-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
West Ward	VITAMIN A	vitamin a palmitate	CAPSULE;ORAL	080967-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Banner Pharmacaps	VITAMIN A PALMITATE	vitamin a palmitate	CAPSULE;ORAL	083981-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Elkins Sinn	VITAMIN A	vitamin a palmitate	CAPSULE;ORAL	085479-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Chase Chem	VITAMIN A	vitamin a palmitate	CAPSULE;ORAL	080746-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 24, 2026

Vitamin A is not a single FDA-approved “brand drug” with one Orange Book listing; it is a broad nutritional and therapeutic ingredient used across multiple oral and injectable products (retinol, retinyl palmitate, acetate, beta-carotene formulations, and related retinoids in some contexts). Investment fundamentals therefore depend on the specific jurisdictional “product” being targeted: whether the commercial exposure is to prescription medicine, dietary supplement, or OTC vitamin-and-mineral combination products, and whether the manufacturer sells a regulated dosage form with drug labeling.

Hard investment bottom line: the addressable IP moat for “Vitamin A” is typically narrow at the ingredient level and highly product/formulation and process-specific. Most opportunities sit in (1) branded delivery systems and stability-preserving formulations, (2) regulatory-compliant manufacturing capacity, and (3) niche indications or high-purity grades. Generic competition risk is structural once a product’s regulatory exclusivity and any formulation IP expire.

What is “Vitamin A” as a drug investment category? Is it prescription, OTC, or a supplement?

Featured snippet answer: Vitamin A investment exposure is fragmented across regulated drug products (prescription/OTC) and non-drug nutrition/supplement channels; each has different pricing power and IP tail risk.

Core actives that typically trade under “Vitamin A”

Retinol (Vitamin A alcohol)
Retinyl esters (commonly retinyl palmitate or retinyl acetate)
Beta-carotene (pro-vitamin A; sometimes used for conversion to retinol)
Retinoids (related class) can be miscategorized as “Vitamin A” in commercial discussions, but patent estates and regulatory pathways differ materially (these are typically true drug actives with distinct exclusivity).

Where the money usually is

Therapeutic-grade products for deficiency correction in clinical settings
Neonatal and pediatric dosing products that require precise formulation and stability
High-reliability supply contracts with wholesalers and health systems
Global markets where fortification rules drive demand (less IP-driven)

How to interpret “fundamentals” for an ingredient-level category

Because Vitamin A is widely sourced and often non-patent-protected at the raw ingredient level, fundamentals typically track:

Cost and yield economics of retinoid manufacture
Supply chain continuity (feedstock availability, contamination risk)
Regulatory compliance and GMP track record
Shelf life, moisture/oxygen sensitivity, and packaging validation
Competition intensity by dosage form (capsules vs liquids vs injectable)

What patents protect vitamin A products, formulations, and manufacturing processes? How many patents cover it?

Featured snippet answer: Vitamin A’s patent coverage is usually dominated by formulation/stability and process patents, with fewer broad composition-of-matter patents at the ingredient level due to long historical development.

Typical patent buckets relevant to Vitamin A

Formulation patents
- Antioxidant systems (e.g., tocopherols), chelators, stabilizers
- Solubilization and particle engineering (for dispersions)
- Coated beads, emulsion systems, and protected-release capsules
Manufacturing process patents
- Esterification routes (retinyl ester synthesis)
- Purification and crystallization methods
- Contamination control (isomer profile, solvent removal, oxidation control)
Dosage form patents
- Injectable vehicle compositions and sterilization compatibility
- Oral liquid preservative systems
- Packaging/closure systems linked to oxidation protection (sometimes indirect)

How many patents cover “Vitamin A”?

A complete quantified count requires a specific product and jurisdictional patent search. Without anchoring to a named drug product (brand/generic) and an FDA label, any “how many patents” number would be non-actionable and potentially wrong.

When does Vitamin A lose exclusivity? What is the Orange Book status of “Vitamin A”?

Featured snippet answer: “Vitamin A” as a category generally does not map to a single Orange Book entry. Orange Book status is product-specific, not ingredient-generic.

Why “Orange Book status of Vitamin A” is usually not a single answer

The Orange Book is tied to approved drug products and specific strengths/dosage forms.
Vitamin A is used in many formulations and often sold as generics or as nutrient supplements outside the Orange Book construct.

Investment implication

Exclusivity timelines should be modeled at the product level:

If the commercial product is already generic with no listed patents, entry risk is immediate.
If the product has listed patents for specific formulations or methods, the tail depends on those listed patent terms and any Hatch-Waxman patent expiry sequencing.

Which companies are major suppliers of Vitamin A drug products and intermediates?

Featured snippet answer: Vitamin A market leadership is commonly concentrated in manufacturers of retinoid APIs and formulation firms, with downstream competition among generic capsule/liquid manufacturers.

Investment-relevant supplier map (how to structure diligence)

API producers (retinol/retinyl ester intermediates)
Finished dose form manufacturers (capsules, softgels, oral liquids)
Injectables suppliers (where relevant)
Contract manufacturers with validated stability programs and packaging controls

Without the target SKU (e.g., “retinyl palmitate capsules X IU” or “injectable Vitamin A formulation Y”), listing company names risks mixing unrelated businesses and confusing nutritional suppliers with drug-product makers.

How strong is the patent estate for Vitamin A: formulation IP or process IP?

Featured snippet answer: For Vitamin A, the typical “strength” is moderate-to-low at broad ingredient claims and higher (but still product-limited) at stability-preserving formulation and manufacturing process claims.

What usually drives enforceability

Claim scope around specific stabilizer systems and concentrations
Specific ratios and manufacturing controls rather than broad “any retinyl ester composition”
Whether competitors can design around by changing excipients, oxygen scavengers, or packaging

What usually weakens enforceability

Long-standing public knowledge of retinoid formulation strategies
Weak breadth of survival against obviousness-type combinations
Generic substitution of excipients and release profiles

What generic entry risks exist for Vitamin A? Paragraph IV or biosimilar-style risks?

Featured snippet answer: Paragraph IV risks exist only for specific FDA-approved drug products with Orange Book-listed patents. Biosimilar risk is generally not applicable unless the product is a biologic, which Vitamin A usually is not.

Paragraph IV risk modeling approach

For each SKU with listed patents:

Identify earliest listed patent expiry date(s)
Model 180-day exclusivity triggers if multiple filers exist
Evaluate whether listed patents are formulation or method-of-use claims that can be designed around by changing excipients or manufacturing routes

Design-around likelihood for Vitamin A

High when patents are narrow and focus on specific excipient systems:

Alternative antioxidants and vehicles
Different ester forms with equivalent bioavailability claims
Modified release or packaging changes

How does Vitamin A compare with other retinoids (e.g., isotretinoin, tretinoin) for investment risk and IP?

Featured snippet answer: Vitamin A generally has lower “drug-like” IP intensity than regulated prescription retinoids with single-agent branded histories and strong method-of-use or composition patents.

Key differences that matter commercially

Regulatory pathway and clinical positioning
- Vitamin A deficiency correction: nutrient/deficiency framework
- Retinoids like isotretinoin: oncology/dermatology drug frameworks with tighter prescribing and labeling controls
IP posture
- Retinoids often have more defensible drug-specific patent estates
- Vitamin A often behaves like an ingredient with formulation and manufacturing moats

What formulations are protected by patents for Vitamin A (capsules, liquids, injectables)?

Featured snippet answer: Protection, when it exists, is usually tied to specific excipient/stabilizer systems and dosage form design, not the mere presence of Vitamin A.

Formulation areas to diligence

Softgel shell chemistry and oxygen barrier properties
Emulsion droplet size and surfactant systems for oral liquids
Antioxidant inclusion and assay stability (impurity profile over shelf life)
Water activity limits and microbial control for liquids

Regulatory consequence

If stability and shelf-life specifications are central to approval, manufacturing changes can drive re-testing and regulatory commitments that raise barriers for entrants.

What patent litigation affects Vitamin A products? Are there notable settlements?

Featured snippet answer: Patent litigation for “Vitamin A” is not typically concentrated at the ingredient level; when disputes occur, they tend to be formulation or specific product patent contests.

A litigation and settlement map requires anchoring to named FDA products and their listed patents. Without SKU-level identification, any “notable cases” list would be unreliable.

What is the FDA regulatory status of Vitamin A products? What pathways and controls apply?

Featured snippet answer: Vitamin A products are commonly marketed under conventional drug application routes if they are drug-labeled; otherwise they may be dietary supplements subject to different regulatory standards.

Investment-relevant FDA issues

cGMP compliance and inspection history
Stability data and expiration dating
Specification control for oxidative degradation products
Labeling classification (drug deficiency treatment vs supplement nutrition claims)

Commercial fundamentals: demand, pricing power, and margin structure for Vitamin A products

Featured snippet answer: Vitamin A demand is driven by deficiency treatment, fortification, and supply stability. Pricing power depends on formulation differentiation and compliance-driven scarcity.

Demand drivers

Maternal and pediatric deficiency management programs
Health-system formularies for deficiency correction
Global fortification programs (more procurement than brand-driven sales)
Natural disaster or supply disruption dynamics (can temporarily lift pricing)

Pricing and margin mechanics

API competition compresses ingredient-level margins
Finished dosage differentiation (softgels, stabilized liquids, injectables) can sustain higher margins
Working capital swings if retinoid intermediates become constrained

Risk factors

Oxidation and quality failures that force recalls or lot rejections
Regulatory enforcement for deviations in impurity profiles
Fast genericization of straightforward dosage forms
Customer concentration in tender-driven procurement

Investment thesis scenarios for Vitamin A: what are plausible deal structures and value drivers?

Featured snippet answer: The most investable scenarios are SKU-level defensibility and manufacturing reliability rather than broad ingredient ownership.

Scenario 1: Acquire a stabilized finished-dose brand with a defensible shelf-life/packaging profile

Value driver: extended commercialization time if formulation patents and regulatory commitments exist
Downside: rapid generic pass-through if patents are weak or already expired

Scenario 2: Secure supply-side advantage in API or high-purity intermediates

Value driver: lower cost of goods, higher yield, fewer quality issues
Downside: commodity-like pricing pressure and customer contract renegotiation

Scenario 3: License or partner for a niche dosage form (e.g., pediatric or injectable where applicable)

Value driver: reduced contestability due to manufacturing validation burden
Downside: regulatory change risk and plant-specific execution risk

Key takeaways

“Vitamin A” is an ingredient/category, not a single IP and regulatory unit; exclusivity, Orange Book status, and patent strength are product-specific.
Patent moats, when present, are usually concentrated in formulation stability and manufacturing/process claims, which competitors can often design around by changing excipients or process controls.
Investment fundamentals tend to be dominated by manufacturing reliability, stability and quality specs, and supply-chain economics, with less ingredient-level patent-driven pricing power.
Generic entry risk is structural: without SKU-level listed patents and active exclusivities, entrants can compete quickly on formulation alternatives.

FAQs

Is Vitamin A patented in the US or is it mostly generic?
Patent protection for Vitamin A is typically formulation/process-specific and SKU-dependent rather than broad ingredient-level exclusivity.
Does Vitamin A have Hatch-Waxman exclusivity or Orange Book patents?
Only specific FDA-approved drug products have Orange Book listings; Vitamin A as a category does not.
What dosage forms are hardest to genericize for Vitamin A?
Typically stabilized softgels, particular oral liquid systems, and any injectable products with tightly controlled vehicles and stability profiles.
What quality issues most affect Vitamin A manufacturing and margins?
Oxidative degradation, impurity/assay drift, and packaging-related oxygen ingress leading to lot rejections.
How should an investor underwrite Vitamin A market growth and risk?
By modeling SKU-level demand from deficiency-treatment programs plus fortification procurement cycles, then stress-testing against generic substitution rates and supply interruptions.

References (APA)

FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/

US Patents:	0
Applicants:	13
NDAs:	25

AI Deep Research

Questions you can ask:

Summary for VITAMIN A